Details of the Drug Combinations

General Information of This Drug (ID: DMM4U9G)

• Drug Name: R0-93877 (DMM4U9G)
• Synonyms: Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]

Indication

Constipation; ICD 11: DD91.1; Status: Approved [1]; Irritable bowel syndrome; ICD 11: DD91.0; Status: Approved [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
R0-93877 + Panobinostat	DCSPJ9J	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
R0-93877 + Idarubicin	DCOLGGH	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
R0-93877 + Famotidine	DC53782	Famotidine	Esophageal Motility Disorders	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT05455359) Gastrointestinal Dysmotility on Aspiration Risk